This study is looking at a drug called lorlatinib for people with advanced non-small cell lung cancer (NSCLC) that has a specific change in the ALK gene. Lorlatinib is a type of medicine called a kinase inhibitor, which targets certain proteins in cancer cells. You might be able to join if you have stage IV or recurrent NSCLC and your cancer has the ALK gene change, confirmed by specific tests. The study will first treat participants with lorlatinib for 12 weeks. Researchers want to see if adding local consolidation therapy (LCT) to lorlatinib helps people live longer without their cancer getting worse, and they will also look at the safety of these treatments. The study aims to enroll 30 participants, but its current status is unclear.

Study design

This is an open-label, multicenter, randomized phase 2 trial. It plans to enroll 30 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.